Welcome to our dedicated page for Intellia Therapeutics news (Ticker: NTLA), a resource for investors and traders seeking the latest updates and insights on Intellia Therapeutics stock.
Intellia Therapeutics, Inc. reports clinical, regulatory and financing developments as a clinical-stage biopharmaceutical company using CRISPR gene editing and other core technologies. Its recurring updates center on in vivo and ex vivo therapeutic approaches for genetically defined diseases, including lonvoguran ziclumeran, or lonvo-z, for hereditary angioedema and nexiguran ziclumeran, or nex-z, for ATTR amyloidosis with cardiomyopathy and polyneuropathy.
Company announcements also cover Phase 3 clinical data, FDA interactions, biologics license application activity, quarterly financial results, common stock offerings, equity incentive grants and investor conference participation. These updates reflect Intellia's progress from gene-editing research and clinical development toward regulatory and commercial planning for its lead programs.
Intellia Therapeutics (NTLA) received FDA acceptance and Priority Review of its Biologics License Application for lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE), with a PDUFA target action date of March 10, 2027.
The FDA also advised that it is not currently planning to hold an advisory committee meeting on the application. Lonvo-z is positioned, if approved, to be the world’s first in vivo CRISPR-based therapy and the only one-time treatment for HAE. The BLA is supported by the global Phase 3 HAELO trial in 80 adults and adolescents (≥16 years) with Type 1 or Type 2 HAE, evaluating a single 50 mg dose.
HAELO met its primary and all key secondary endpoints, showing an 87% reduction in mean monthly attacks versus placebo from weeks 5 to 28 (p<0.0001). During the six-month efficacy period, 62% of lonvo-z patients were attack free and HAE-therapy free, versus 11% on placebo (p<0.0001). No serious adverse events occurred in the lonvo-z arm; all treatment emergent events were mild or moderate.
Intellia Therapeutics (NTLA) reported that on September 1, 2026 it granted inducement equity awards to 41 new employees under its 2024 Inducement Plan, as amended.
The awards consist of time-based restricted stock units covering an aggregate of 163,100 shares of common stock. One-third of each RSU award will vest annually over three years, subject to continued service with Intellia through each vesting date. These grants were made outside the stockholder-approved equity plans under the 2024 Inducement Plan, which was initially adopted by the board in June 2024, and were approved by the compensation committee as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (NTLA) entered a non-dilutive senior secured term loan facility of up to $400 million with OrbiMed.
The facility provides $75 million funded at closing and up to $325 million in additional capital. Five milestone-based tranches total up to $225 million, primarily linked to lonvoguran ziclumeran (lonvo-z), with a further $100 million available by mutual agreement during the five-year term. The company said the financing supports a planned U.S. approval and commercial launch of lonvo-z for hereditary angioedema, advancement of nexiguran ziclumeran in transthyretin amyloidosis, and early pipeline development.
Intellia Therapeutics (NTLA) will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, at 4:05 p.m. ET.
A live webcast will be accessible via the Events and Presentations page in the Investors & Media section of Intellia’s website, with a replay available for approximately 90 days.
Intellia Therapeutics (Nasdaq: NTLA) reported that on August 1, 2026, it granted inducement equity awards to eight new employees under its 2024 Inducement Plan, as amended. The awards consist of time-based restricted stock units covering an aggregate of 38,200 shares of common stock, with one-third of the RSUs vesting annually over three years, subject to continued service. According to Intellia, these grants were made outside its stockholder-approved equity incentive plans under the 2024 Inducement Plan adopted in June 2024 and were approved by the compensation committee as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (Nasdaq: NTLA) reported second quarter 2026 results highlighted by positive Phase 3 HAELO data for lonvoguran ziclumeran (lonvo-z) in hereditary angioedema. A one-time infusion reduced attacks by 87% versus placebo over weeks 5–28, met all key secondary endpoints with p<0.0001, and showed no serious adverse events in the lonvo-z arm.
The company expects FDA acceptance of its lonvo-z BLA in the second half of 2026 and is planning for a potential U.S. launch in the first half of 2027. Intellia also advanced nexiguran ziclumeran (nex-z) Phase 3 ATTR programs, integrating new genomic insights and targeting MAGNITUDE-2 enrollment completion in the second half of 2026. Cash, cash equivalents and marketable securities were $628.4 million at June 30, 2026, supported by a $195 million equity offering and expected to fund operations at least into 2028.
Intellia Therapeutics (Nasdaq: NTLA) will host a conference call and webcast on August 6, 2026 at 8:00 a.m. ET to discuss its second quarter 2026 financial results and business updates. U.S. investors can dial 1-833-316-0545, international participants 1-412-317-5726, and a replay will be accessible for about 90 days via the Events page in the Investors & Media section of Intellia’s website.
Intellia Therapeutics (Nasdaq: NTLA) granted inducement equity awards to thirteen new employees on July 1, 2026, under its 2024 Inducement Plan.
The awards comprise time-based restricted stock units for an aggregate of 53,250 common shares, vesting in three equal annual installments, subject to continued service, and were approved under Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (Nasdaq: NTLA) reported additional positive Phase 3 HAELO data for lonvoguran ziclumeran (lonvo-z) in hereditary angioedema.
Lonvo-z achieved an 87% reduction in mean monthly attacks vs placebo and showed large decreases in treated and moderate/severe attacks, improved AE-QoL scores, favorable safety, and supports a rolling BLA with a potential U.S. launch targeted for 1H 2027.
Intellia Therapeutics (Nasdaq: NTLA) granted equity awards to six new employees under its 2024 Inducement Plan. On June 1, 2026, they received time-based RSUs for an aggregate 47,150 common shares, vesting in three equal annual installments over three years.
The awards were approved by the compensation committee as a material inducement to employment and granted outside stockholder-approved plans, in line with Nasdaq Listing Rule 5635(c)(4). Vesting requires continued service with Intellia.